D.E. Shaw & Co’s TG Therapeutics TGTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.34M Sell
59,800
-17,900
-23% -$969K ﹤0.01% 2798
2026
Q2
$4.27M Buy
77,700
+62,500
+411% +$2.56M ﹤0.01% 2527
2026
Q1
$505K Sell
15,200
-52,900
-78% -$1.58M ﹤0.01% 3856
2025
Q4
$2.03M Sell
68,100
-17,700
-21% -$578K ﹤0.01% 3039
2025
Q3
$3.1M Sell
85,800
-21,500
-20% -$708K ﹤0.01% 2618
2025
Q2
$3.86M Buy
107,300
+44,800
+72% +$1.67M ﹤0.01% 2228
2025
Q1
$2.46M Buy
62,500
+6,600
+12% +$222K ﹤0.01% 2453
2024
Q4
$1.68M Buy
+55,900
New +$1.6M ﹤0.01% 2855
2024
Q3
– Sell
-18,400
Closed -$327K – 4888
2024
Q2
$327K Buy
+18,400
New +$294K ﹤0.01% 3843
2024
Q1
– Sell
-11,200
Closed -$191K – 4734
2023
Q4
$191K Hold
11,200
– – ﹤0.01% 3888
2023
Q3
$93.6K Hold
11,200
– – ﹤0.01% 3859
2023
Q2
$278K Buy
+11,200
New +$289K ﹤0.01% 3621
2020
Q3
– Sell
-50,000
Closed -$974K – 4158
2020
Q2
$974K Buy
+50,000
New +$805K ﹤0.01% 2959
2018
Q2
– Sell
-21,900
Closed -$311K – 3894
2018
Q1
$311K Buy
+21,900
New +$280K ﹤0.01% 3132

Other funds holding TGTX

D.E. Shaw & Co's TGTX Position: Q3 2026 in Review

D.E. Shaw & Co reduced its TG Therapeutics (TGTX) stake by 3.6% in Q3 2026, selling an estimated $6.58M and leaving 3,279,204 shares worth $183M. The position accounts for 0.09% of the portfolio, ranked #253.

D.E. Shaw & Co first reported a position in TGTX in Q1 2015 and has held it in 41 quarters since. The position peaked at $187M in Q2 2026. 454 funds tracked by Wall St. Rank hold TGTX as of Q3 2026.

  • D.E. Shaw & Co held 3,279,204 shares of TG Therapeutics worth $183M as of Q3 2026.
  • D.E. Shaw & Co sold 121,604 TG Therapeutics shares in Q3 2026, an estimated $6.58M.
  • TG Therapeutics made up 0.09% of D.E. Shaw & Co's portfolio in Q3 2026, its #253 holding.
  • D.E. Shaw & Co first reported a position in TG Therapeutics in Q1 2015 and has held it in 41 quarters since.
  • D.E. Shaw & Co's TG Therapeutics position peaked at $187M in Q2 2026.
  • 454 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2026.

Based on D.E. Shaw & Co's 13F filing for Q3 2026, filed 16 Nov 2026.